Magstim’s Horizon TMS Therapy to treat major depressive disorder. Credit: PRNewsfoto/Magstim.

UK-based Magstim has launched its new Horizon transcranial magnetic stimulation (TMS) therapy to treat adults with major depressive disorder (MDD).

The technology platform is indicated for patients who could not achieve satisfactory improvement while using antidepressant drugs.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Claimed to be safe and cost-effective, the Horizon platform features a focused electromagnetic coil that quickly delivers a magnetic field to the target brain area.

The non-invasive, non-systemic TMS procedure is performed through emission of a series of repetitive, brief and focused magnetic pulses for activating brain cells and restoring brain activity level to normal.

Horizon includes an energy recovery system designed to provide easy, consistent stimulation while decreasing maintenance.

“Horizon will form the basis for additional innovations that bring new hope to the millions who have been living with depression.”

Magstim Group CEO Lothar Krinke said: “Horizon is Magstim’s next-generation technology platform for TMS applications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As we build on our proven record in research and continued expansion in the clinical market, we are confident that Horizon will form the basis for additional innovations that bring new hope to the millions who have been living with depression.”

The technology platform obtained CE-Mark as well as clearance from the US Food and Drug Administration (FDA) for treating patients who failed to improve from prior antidepressant medication in the current episode.

Magstim developed TMS as a research tool and optimised it for the treatment of nerve and brain conditions. The firm currently offers various research and clinical application products for different medical and research companies.